Loading Ticker...
You Are Here: Home » Pharma

Cost Trimming and Vaccine sales, Help boost GSK Pharma Q4 Profits

Drug-maker GlaxoSmithKline Pharmaceuticals sees profits improve, due to continued growth of vaccines and specialty products, tighter expense control and new product launches for the 4th quarter of 2011.

Glaxosmithkline GSK Pharmaceuticals Logo

Glaxosmithkline GSK Pharmaceuticals Logo

According to DrHasit B. Joshipura, Managing Director of GSK (India), the company was able to register good growth in its specialty business, thanks to the launch of products from its global pipeline and branded generics. The vaccine segment witnessed tremendous growth, as then company continues to expand its vaccine portfolio.

The company launched Synflorix in the quarter, a vaccine against invasive pneumococcal disease, which is the leading contributor of child mortality in India. GSK pharma also expanded its oncology portfolio, after launching a treatment of advanced renal cell carcinoma called Votrient and treatment for reduced platelet count called RevoladeTM.

The company’s board recommended a dividend payout of Rs 45, compared to the previous year Rs 40.


Share this post

Subscribe to our updates via e-mail or get our  RSS Feed
Enter your email address:

Other Related Stories: